No Data
No Data
Evercore Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Raises Target Price to $60
Akero Therapeutics Insider Sold Shares Worth $2,243,213, According to a Recent SEC Filing
Insider Sale: Chief Operating Officer of $AKRO Sells 11,447 Shares
Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (AKRO), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)
Akero Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Akero Therapeutics Analyst Ratings